Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249800 | 1.00 | CES1 (0.43) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL527656 | 1.00 | CES1 (0.43) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL15895048 | 0.88 | CES1 (0.42) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL236357 | 0.87 | CES1 (0.47) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL246914 | 0.87 | CES1 (0.47) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL236358 | 0.87 | CES1 (0.47) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| Hydrochloric Acid SCHEMBL8829227 | 0.85 | CES1 (0.46) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| Hydrochloric Acid SCHEMBL4926039 | 0.85 | CES1 (0.46) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| Hydrochloric Acid SCHEMBL5595770 | 0.85 | CES1 (0.46) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL7436744 | 0.84 | CES1 (0.44) | CES1KCNN4ENPP2CYP1A2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114624351-B | Analysis method of (R) - (-) -1-amino-2-propanol residues in pomazolam besylate bulk drug | 宜昌人福药业有限责任公司 | 2024-04-09 | — | — | CN | claimed |
| US-11760750-B1 | Process for preparing levoketoconazole | NURAY CHEMICALS PRIVATE LIMITED (IN) | 2023-09-19 | — | — | US | claimed |
| CN-114624351-A | Analysis method for (R) - (-) -1-amino-2-propanol residue in benzene sulfonic acid remazolam bulk drug | 宜昌人福药业有限责任公司 | 2022-06-14 | — | — | CN | claimed |
| CN-103175919-B | Gas chromatography-mass spectrometry combined detection method for -NNAL and (R) -NNAL in urine | HONGYUN HONGHE TOBACCO GROUP | 2014-07-02 | — | — | CN | claimed |
| CN-103175919-A | Gas chromatography-mass spectrometry combined detection method for -NNAL and (R) -NNAL in urine | HONGYUN HONGHE TOBACCO GROUP | 2013-06-26 | — | — | CN | claimed |
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250207131-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-06-26 | — | — | US | disclosed |
| CN-117964706-B | Fifteen-membered cyclic depsipeptide compound and preparation method and application thereof | 广西中医药大学 | 2025-05-20 | — | — | CN | disclosed |
| US-12275938-B2 | Modified RNA agents with reduced off-target effect | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12247203-B2 | Modified RNA agents with reduced off-target effect | ALNYLAM PHARMACEUTICALS, INC. | 2025-03-11 | — | — | US | disclosed |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| WO-1991006536-A1 | METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-05-16 | — | — | WO | disclosed |
| US-4912042-A | Incubation, separation of mixture | EASTMAN KODAK COMPANY (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0325971-A2 | Process for the preparation of optically pure hydroxyarylalkanoic acids and esters | F. HOFFMANN-LA ROCHE AG (CH) | 1989-08-02 | — | — | EP | disclosed |
| EP-0319471-A2 | Resolution process | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | disclosed |
| US-4772727-A | Method of producing enantiomerically pure R-(+)-alpha-lipoic acid and S-(-)a | DEGUSSA (DE) | 1988-09-20 | — | — | US | disclosed |
| EP-0270596-A1 | A STEREOCONSERVATIVE SYNTHESIS OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THERETO | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1988-06-15 | — | — | EP | disclosed |
| EP-0261336-A2 | Process for the preparation of pure enantiomers of R-(+)-alpha-lipoic acid and S-(-)-alpha-lipoic acid (thioctic acid), and nonene or mesyl derivatives as intermediates therefor | ASTA Medica Aktiengesellschaft (DE) | 1988-03-30 | — | — | EP | disclosed |
| WO-1987007271-A1 | A STEREOCONSERVATIVE SYNTHESIS OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THERETO | Astra Läkemedel Aktiebolag (SE) | 1987-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A43, F12 | CES1 2017/4885KCNN4 1533/4885ENPP2 3052/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | CES1 1493/4885KCNN4 938/4885ENPP2 1332/4885 |
| US-12109219-B2 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | CES1 1048/4885KCNN4 2652/4885ENPP2 790/4885 |
| US-11760750-B1 | Process for preparing levoketoconazole | KHK, KYAT3, PLK3 | CES1 558/4885KCNN4 3027/4885ENPP2 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.